Jalon(688357)
Search documents
建龙微纳:董事会提名委员会议事规则
2024-04-18 11:56
洛阳建龙微纳新材料股份有限公司 董事会提名委员会议事规则 第一章 总则 第一条 为规范洛阳建龙微纳新材料股份有限公司(以下简称"公司")领导人 员的产生,优化董事会、监事会和经营管理机构的组成,完善公司治理结构,根据 《中华人民共和国公司法》《上市公司治理准则(2018年修订)》《洛阳建龙微纳 新材料股份有限公司章程》(以下简称《公司章程》)及其他有关规定,公司特设 立董事会提名委员会,并制定本规则。 第二条 董事会提名委员会是董事会按照股东大会决议设立的专门工作机构,主 要负责对公司董事和经理人员的人选、选择标准和程序进行选择并提出建议。 第三章 职责权限 第八条 提名委员会负责拟定董事和高级管理人员的选择标准和程序,对董事、 高级管理人员人选及其任职资格进行遴选、审核,并就下列事项向董事会提出建 议: (一)提名或任免董事; (二)聘任或解聘高级管理人员; 第二章 人员组成 第三条 提名委员会成员由三名董事组成,独立董事占多数。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事的三分 之一以上提名,并由董事会选举产生。 第五条 提名委员会设召集人一名,由独立董事担任,负责主持委员会工作;召 ...
建龙微纳:2023年度独立董事述职报告—王瞻
2024-04-18 11:56
洛阳建龙微纳新材料股份有限公司 2023 年度独立董事述职报告(王瞻) 本人作为洛阳建龙微纳新材料股份有限公司(以下简称"公司")的独立董事, 严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董事管理办 法》《上海证券交易所科创板股票上市规则》等法律法规及《公司章程》等规定, 本着认真负责的态度,忠实勤勉的履行独立董事的义务和职责,积极参加公司 2023年召开的股东大会、董事会及董事会各专门委员会等相关会议,认真审议董 事会各项议案,对公司相关重大事项均发表了独立意见,充分发挥了作为独立董 事的专业优势及独立作用,现将2023年度主要工作情况报告如下: 一、本人的基本情况 (一)个人工作履历、专业背景以及兼职情况 本人王瞻,2019年3月至今,任公司独立董事。曾任成都瀚江新材料科技股 份有限公司董事、副总经理,安徽吉曜玻璃微纤有限公司总经理;2012年7月至 今,任青澜(上海)酒业有限公司监事;2018年5月至今任上海兰迪律师事务所 高级合伙人。 亲自出席了4次审计委员会会议、1次提名委员会会议。本人对提交董事会和股东 大会的议案均进行了认真审议,并与公司经营管理层保持了充分沟通,积极关注 公司 ...
建龙微纳:关于第三届董事会第31次会议相关事宜的独立意见
2024-04-18 11:56
洛阳建龙微纳新材料股份有限公司 关于第三届董事会第 31 次会议相关事宜的独立意见 我们作为洛阳建龙微纳新材料股份有限公司(以下简称"公司")的独立董 事,根据《中华人民共和国公司法》《上市公司独立董事管理办法》《公司章程》 《独立董事工作制度》等的规定,基于独立、审慎、客观的立场,对第三届董事 会第 31 次会议所审议的相关事项发表独立意见如下: (一)《关于<2023年度内部控制评价报告>的议案》的独立意见 我们认为:公司已经建立了较为完善的内部控制体系和内部管理制度,覆盖 了公司生产经营的各环节,并能够得到有效执行。公司编制的《2023年度内部控 制评价报告》真实、完整、客观地反映了公司的内部控制状况和各项管理制度的 建立健全情况,不存在明显薄弱环节和重大缺陷。 我们认为:公司根据实际情况需要变更公司注册资本和对《公司章程》修订 和完善,符合《中华人民共和国公司法》等相关法律、法规及《公司章程》的相 关规定,不存在损害本公司和中小股东利益的情形。 因此,我们同意该项议案并同意提交公司 2023年年度股东大会审议。 (四)《关于续聘会计师事务所的议案》的独立意见 我们认为:立信会计师事务所(特殊普通合伙) ...
建龙微纳:独立董事专门会议工作制度
2024-04-18 11:56
洛阳建龙微纳新材料股份有限公司 独立董事专门会议工作制度 第三条 独立董事对本公司及全体股东负有忠实与勤勉义务,应当按照法 律、行政法规、中国证券监督管理委员会(以下简称"中国证监会")规定、证 券交易所业务规则和公司章程的规定,认真履行职责,在董事会中发挥参与决策、 监督制衡、专业咨询作用,维护上市公司整体利益,保护中小股东合法权益。 第四条 公司应当定期或不定期召开独立董事专门会议。原则上应于会议 召开前三天通知全体独立董事。但情况紧急或遇特殊情况,需要尽快召开独立董 事专门会议的,应即时通知,及时召开,但召集人应当在会议上作出说明并记载 于独立董事专门会议记录。 第五条 独立董事专门会议可以采取通讯表决的方式召开;半数以上独立 董事可以提议可召开临时会议。 第六条 独立董事应当亲自出席独立董事专门会议,因故不能亲自出席会 议的,应当事先审阅会议材料,形成明确的意见,并书面委托其他独立董事代为 出席。 第七条 独立董事专门会议设召集人一名,由过半数独立董事共同推举产 生,负责召集和主持会议;召集人不履职或者不能履职时,两名及以上独立董事 可以自行召集并推举一名代表主持。 第八条 下列事项应当经公司独立董事 ...
建龙微纳(688357) - 2023 Q4 - 年度财报
2024-04-18 11:56
Financial Performance - The company's operating revenue for 2023 was approximately ¥972.24 million, representing a year-on-year increase of 13.87%[21]. - The net profit attributable to shareholders decreased by 22.65% to approximately ¥153.03 million, while the net profit after deducting non-recurring gains and losses fell by 11.32% to approximately ¥136.89 million[23]. - The company reported a basic earnings per share of ¥1.84, down 23.01% compared to the previous year, and a weighted average return on equity of 9.06%, a decrease of 4.83 percentage points[23]. - The net cash flow from operating activities was negative at approximately -¥97.84 million, a decline from -¥32.59 million in the previous year[21]. - The company achieved operating revenue of 972.24 million yuan, representing a year-on-year growth of 13.87%, while net profit decreased by 22.65% to 153.03 million yuan[52]. - The company's diluted earnings per share for 2023 was CNY 1.72, down 27.73% from CNY 2.38 in the previous year[66]. - The company's weighted average return on equity for 2023 was 9.06%, a decrease of 4.83 percentage points from 13.89% in 2022[66]. - The net asset return rate, excluding non-recurring gains and losses, was 8.11% for 2023, down 2.72 percentage points from 10.83% in 2022[66]. Assets and Investments - Total assets increased by 38.57% to approximately ¥3.03 billion, and net assets attributable to shareholders rose by 14.80% to approximately ¥1.78 billion[23]. - The company issued convertible bonds during the reporting period, contributing to the growth in total assets and net assets[23]. - The company plans to distribute a cash dividend of ¥6 per 10 shares and to increase capital by converting reserves into 2 additional shares for every 10 shares held[3]. Research and Development - The company aims to enhance its product competitiveness and market share through increased investment in R&D and talent acquisition, which has led to higher management expenses[23]. - Research and development expenses increased by 30%, focusing on new technologies in the field of molecular sieves[47]. - The company added 8 new authorized invention patents during the reporting period, emphasizing its commitment to R&D and innovation[102]. - The company has established several joint laboratories with universities and research institutes to enhance its R&D capabilities and innovation[123]. - The company has invested a total of CNY 26,997,419.95 in R&D projects this period, with a cumulative investment of CNY 37,259,972.54[127]. - The R&D personnel count has increased to 86, representing 11.39% of the total workforce, with an average salary of CNY 161,809.81[151]. Market Expansion and Strategy - The company is focused on expanding its product applications and market presence to support long-term growth[23]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[47]. - A strategic acquisition of a competitor is anticipated to enhance the company's product offerings and market reach, expected to be finalized in Q2 2024[47]. - The company is leveraging advancements in technology to accelerate the import substitution of molecular sieve products in various downstream applications[112]. - The company is actively involved in addressing VOCs pollution, which has become a key focus in China's air pollution prevention efforts[142]. Sales and Revenue Growth - The company’s overseas sales revenue reached 175.56 million yuan, an increase of 44.87% compared to the previous year, reflecting strong growth in international markets[55]. - New product sales revenue amounted to approximately 24.00 million yuan, showing a significant increase of 354.94% year-on-year, driven by sales in automotive brake systems and air suspension systems[58]. - The gas separation sector accounted for 36.76% of total revenue, with a slight decline of 4.50% year-on-year, while the medical health sector contributed 30.66% with a growth of 25.80%[53]. - The gross margin improved to 35%, up from 30% in the previous year, due to cost optimization measures[47]. - The company launched two new products in Q4 2023, contributing to a 5% increase in overall sales[47]. Operational Efficiency - The company aims to reduce operational costs by 10% through efficiency improvements in the supply chain[47]. - Operating costs rose by 18.32% year-on-year to approximately ¥677.80 million, primarily due to increased sales scale[198]. - Sales expenses surged by 42.99% year-on-year to approximately ¥25.92 million, attributed to intensified efforts in new product development and market promotion[198]. - Management expenses increased by 24.28% year-on-year to approximately ¥70.79 million, mainly due to higher personnel costs for talent acquisition[198]. - The company has optimized its production processes to reduce costs and improve product quality, including the use of high-efficiency drying techniques and vacuum roasting[170]. Corporate Governance and Social Responsibility - The company received the highest rating of A for information disclosure from the Shanghai Stock Exchange, highlighting its commitment to transparency and corporate governance[62]. - The company actively participates in social responsibility initiatives, including education and poverty alleviation, aligning economic and social benefits[62]. - The company has received recognition as a high-tech enterprise, which allows for a reduced corporate income tax rate of 15% for three years starting from the year of certification[166]. Risks and Challenges - The company faces risks related to product iteration and the need for continuous R&D investment to maintain market competitiveness[162]. - The company faces risks related to raw material price fluctuations, which could adversely impact performance if product prices do not adjust accordingly[187]. - The company is exposed to potential trade barriers in overseas markets, particularly in the U.S. and Europe, which could negatively affect export sales[185].
建龙微纳:2023年度社会责任报告
2024-04-18 11:56
洛阳建龙微纳新材料股份有限公司 2023年度社会责任报告 致力于为人类美好生活做贡献 2024年4月 目录 | 报告导读 | 02 | | --- | --- | | 走进建龙微纳 | 04 | | 优化公司治理 | 15 | | 强化责任管理 | 31 | | 携手伙伴共赢 | 41 | | 绿色生产运营 | 43 | | 董事会声明 | 45 | | 展望未来 | 47 | 关于前瞻性陈述的风险提示 本报告内容部分章节可能包含前瞻性陈述,旨在反映 公司结合目前实际情况对公司未来做出的预判、对公 司未来的展望以及公司发展目标。这部分陈述存在已 知或未知的风险和不确定性,因此不应作为读者的主 要投资依据。 鉴于社会责任报告相关内容和披露的范围有限,建议 投资者配合公司年度报告及其他信息披露文件一起阅 读。本报告严格遵守适用的相关法律法规。由于已知 或未知的风险和不确定性,前瞻性陈述不反映本报告 发布日期以后发生的事件,建龙微纳不承担与此相关 的任何法律责任。 报告范围: 2023年1月1日~2023年12月31日,部分内容超出上述范围。如无特别说明,本报告范围为建龙微纳 及其下属子公司。 编制依据: 本报告参 ...
建龙微纳:会计师事务所选聘制度
2024-04-18 11:56
洛阳建龙微纳新材料股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为规范洛阳建龙微纳新材料股份有限公司(以下简称"公司")选聘(含续聘、 改聘,下同)执行财务会计报告审计业务的会计师事务所的有关行为,提高财务信息质量, 切实维护股东利益,根据《中华人民共和国公司法》《中华人民共和国证券法》《国有企 业、上市公司选聘会计师事务所管理办法》及《洛阳建龙微纳新材料股份有限公司章程》 (以下简称"《公司章程》")等的有关规定,结合公司实际情况,制订本制度。 第二条 公司选聘执行年度报告审计业务的会计师事务所(以下简称"会计师事务所") 对财务会计报告发表审计意见、出具审计报告,应遵照本制度履行选聘程序。选聘其他专 项审计业务的会计师事务所,视重要性程度可参照本制度执行。 第三条 公司选聘会计师事务所应当经董事会审计委员会(以下简称"审计委员会") 审核后,提交董事会审议,并由股东大会决定,公司不得在董事会、股东大会审议通过前 聘请会计师事务所开展审计业务。 第二章 会计师事务所执业要求 第四条 公司选聘的会计师事务所应当具备下列条件: (一)具有独立的法人资格,具备国家行业主管部门和中国证监会规定的开展证券 ...
建龙微纳:第三届董事会第31次会议决议公告
2024-04-18 11:56
证券代码:688357 证券简称:建龙微纳 公告编号:2024-012 转债代码:118032 转债简称:建龙转债 洛阳建龙微纳新材料股份有限公司 第三届董事会第 31 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 董事会会议召开情况 二、 董事会会议审议情况 本次会议由董事长李建波先生主持,以记名投票方式审议通过了以下议案: (一)审议通过《关于<2023 年度总经理工作报告>的议案》 公司董事会认为总裁带领公司全体员工,协调各个部门展开工作,在生产、 销售、技术研发和内控制度建设等方面均取得了一定的发展。公司董事会同意认 可其工作报告。 表决结果:7 票同意,0 票反对,0 票弃权。 (二)审议通过《关于<2023 年度董事会工作报告>的议案》 公司董事会严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《上海证券交易所科创板股票上市规则》等法律法规及《公司章程》《董事会议 事规则》等公司制度的规定,从切实维护公司利益和广大股东权益出发,认真履 行了股东大会赋予董事会的职责,并按照公司确 ...
建龙微纳:2024年“提质增效重回报”行动方案
2024-04-18 11:56
证券代码:688357 2024 "提质增效重回报"行动方案 洛阳建龙微纳新材料股份有限公司 2024年4月18日 公司特此制定建龙微纳2024 年度"提质增效重回报"行动 方案,并于2024年4月18日 经公司第三届董事会第31次 会议审议通过。 建龙微纳(以下简称"公司" 或"建龙微纳")坚定认为: 提高上市公司质量,增强投 资者回报,提升投资者的获 得感,是上市公司发展的应 有之义,是上市公司对投资 者的应尽之责,公司将持续 优化公司经营、规范治理和 积极回报投资者,提高公司 发展质量,切实保护投资者 利益,助力信心提振。 " 提 质 增 效 重 回 报 " 行 动 方 案 " 提 质 增 效 重 回 报 " 行 动 方 案 洛阳建龙微纳新材料股份有限公司 04 | | | | 01 | 聚焦主业 | 04 | | --- | --- | --- | | | 做大做强分子筛新材料业务 | | | 02 | 聚焦新质生产力 | 09 | | | 加大研发创新 | | | 03 | 优化运营管理 | 13 | | | 提升经营质量与效率 | | | 04 | 健全公司治理 | 16 | | | 筑牢高质量发 ...
建龙微纳(688357) - 2024 Q1 - 季度财报
2024-04-18 11:56
Financial Performance - Basic earnings per share (EPS) fell by 47.95% to 0.38 RMB, while diluted EPS decreased by 52.05% to 0.35 RMB[4] - Net profit attributable to shareholders decreased by 47.74% due to a significant decline in operating revenue and increased marketing expenses[9] - The net profit after deducting non-recurring gains and losses decreased by 52.09%, with period expenses increasing by 5.35 percentage points compared to the previous year[9] - The company reported a gross profit margin of approximately 15.6% for Q1 2024, down from previous levels due to increased costs[32] - The total profit for the quarter was 35,383,302.20 RMB, down from 68,744,645.39 RMB in the same quarter last year, reflecting a decrease of approximately 48.5%[41] - The net profit for the quarter was 31,638,902.18 RMB, compared to 60,546,221.78 RMB in the previous year, representing a decline of about 47.8%[41] - The company reported a basic earnings per share of 0.38 RMB, down from 0.73 RMB in the same quarter last year, indicating a decrease of approximately 48.9%[41] Cash Flow - The net cash flow from operating activities decreased to -29,593,640.87 RMB, a decline of 163.50% compared to the previous year[4] - Cash inflows from operating activities totaled 124,251,392.24 RMB, down from 261,898,980.14 RMB in the previous year[5] - The cash and cash equivalents at the end of the period totaled 733,012,438.61 RMB, a decrease from 802,448,878.91 RMB at the end of the previous period[39] - The cash inflow from investment activities totaled 902,056,169.97 RMB, an increase from 812,302,971.01 RMB in the previous period, showing a growth of about 11.5%[39] - The cash outflow from financing activities was 2,921,824.83 RMB, compared to 666,286.41 RMB in the previous year, indicating a significant increase in cash outflows[41] - The cash flow from financing activities was negative at -2,921,824.83 RMB, contrasting with a positive cash flow of 690,419,913.59 RMB in the previous period, indicating a shift in financing strategy[41] Assets and Liabilities - Total assets decreased by 1.51% to 2,983,507,467.79 RMB compared to the end of the previous year[4] - Total liabilities decreased to ¥1,184,429,802.96 from ¥1,250,471,343.80, indicating a reduction in overall liabilities[28] - Non-current assets increased to ¥1,415,183,430.23 from ¥1,363,831,826.71, showing growth in long-term investments[28] - Current liabilities totaled ¥525,401,368.32, down from ¥597,799,307.45, indicating improved liquidity management[28] Revenue and Market Performance - Operating revenue dropped by 41.18% compared to the same period last year, primarily due to changes in product and customer structure[9] - In Q1 2024, the company achieved revenue of CNY 192 million, a year-on-year decrease of 41.18% but a quarter-on-quarter increase of 11.35%[19] - The company’s foreign sales revenue reached approximately CNY 50.04 million, representing a year-on-year growth of 19.63%[19] - Total operating revenue for Q1 2024 was ¥191,727,092.70, a decrease of 41.18% compared to Q1 2023[36] Research and Development - Research and development (R&D) expenses totaled 8,220,170.93 RMB, a decrease of 40.61% year-over-year, with R&D expenses accounting for 4.29% of operating revenue, an increase of 0.04 percentage points[4] - Research and development expenses for Q1 2024 were ¥8,220,170.93, a decrease from ¥13,840,995.82 in Q1 2023, reflecting a strategic focus on cost management[32] - The company plans to leverage its five joint laboratories to focus on cutting-edge technology research and development, exploring new application scenarios for molecular sieves[20] Strategic Developments - The company has successfully completed the molecular sieve filling for a 240,000-ton/year anhydrous ethanol project for COFCO, marking a significant application expansion[20] - The company’s fifth-generation cryogenic air separation molecular sieve products have been successfully integrated into a Sinopec system, indicating progress in new product development[20] - The company is actively expanding into international markets, particularly in Southeast Asia, where its market share in methane purification has significantly increased[19]